Research programme: eye disorder therapeutics - ACADIA Pharmaceuticals

Drug Profile

Research programme: eye disorder therapeutics - ACADIA Pharmaceuticals

Alternative Names: Glaucoma therapeutics - ACADIA/Allergan

Latest Information Update: 23 Nov 2015

Price : $50

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders; Glaucoma

Most Recent Events

  • 30 Sep 2015 Allergan terminates collaboration agreement with ACADIA Pharmaceuticals for development of muscarinic therapeutics for Glaucoma (ACADIA Pharmaceuticals 10-Q, September 2015)
  • 03 Jun 2013 Allergan progresses an additional undisclosed candidate for Glaucoma into preclinical development
  • 02 Apr 2011 ACADIA Pharmaceuticals extends drug discovery collaboration with Allergan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top